E-Mail
Israel is the first country to report national data on the Pfizer-BioNTech vaccine, with observational analysis showing that two doses provide more than 95% protection against COVID-19 infection, hospitalisation, and death, including among the elderly, at a time when the B.1.1.7 variant was the dominant strain.
A single dose of the vaccine was associated with 58% protection against infection, 76% against hospitalisation, and 77% against death, emphasising the importance of fully vaccinating adults.
Challenges to controlling the pandemic remain, including uncertainty about the duration of immunity, the possible emergence of vaccine-resistant variants, and the need to increase vaccine coverage.
Two doses of the Pfizer-BioNTech COVID-19 vaccine provide more than 95% protection against infection, hospitalisation, severe illness, and death, including among the elderly, according to the first national-level observational assessment of its effectiveness in Israel, published i
The U.S. new cases 7-day rolling average are 10.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 3.4 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 40,531
U.S. Coronavirus deaths are at 890
U.S. Coronavirus immunizations have been administered to 73.8 doses per 100 people.
The 7-day rolling average rate of growth of the pandemic shows new cases improved and deaths were little changed
India s Top Science Adviser Warns of Inevitable Third Wave as Country Grapples With Soaring COVID Cases
India G-7 Delegation Forced To Self-Isolate After Positive Coronavirus Tests
The early data makes a clear case for vaccinating adolescents. But it's also true that humans have an extremely difficult time making a medical choice on another person's behalf and sometimes default to doing nothing.
COVID-19 Severity Starts in Normal BMI Range, Especially in Young medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
But in the future, that could change, either by necessity or by design.
This idea of using two types of vaccines isn t a new concept. It s known as heterologous vaccination, although there s a more colloquial term. In the U.K. at the moment, we re sort of calling it mix and match, says Helen Fletcher, a professor of immunology at the London School of Hygiene & Tropical Medicine. She says shortages of a vaccine or concerns about side effects may induce health officials to adopt a mix-and-match strategy.
Health agencies in France and Germany are already encouraging people who ve gotten the AstraZeneca vaccine to consider getting one of the mRNA vaccines for their second shot.